The effect of ezetimibe and acarbose in treatment of non alcoholic fatty liver disease
Phase 2
- Conditions
- non alcoholic fatty liver disease.Fatty (change of) liver
- Registration Number
- IRCT201109197590N1
- Lead Sponsor
- Vice chancellor for research, Qazvin University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 31
Inclusion Criteria
1- the patients diagnosed by means of ultrasound (Bright liver pattern with liver kidney contrast); 2-ALT more than 40 in men and more than 31 in women; 3-Age above18. Exclusion criteria: 1-Type1 or 2 diabetes mellitus; 2-Positive serology for hepatitis; 3-Alcohol consumption more than 20gr per day; 4-History of renal or liver disease; 5-Using drugs like steroids or drugs that influence energy metabolism, intestinal transit, substrate metabolism.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method iver enzyme, AST, aspartate aminotransferase. Timepoint: Before and 2 months after treatment. Method of measurement: Lab kit.;Liver enzyme, ALT, alanine aminotransferase. Timepoint: Before and 2 months after treatment. Method of measurement: Lab kit.
- Secondary Outcome Measures
Name Time Method Insulin resistance index. Timepoint: Before and 2months after treatment. Method of measurement: Fasting glycemia mmol/L× fasting insulinemiaMIU/L/22 .lab kit.;Inflamation index hs CRP. Timepoint: Before and 2 months after treatment. Method of measurement: Lab kit.